New York State Common Retirement Fund Has $14.53 Million Stock Holdings in Penumbra, Inc. (NYSE:PEN)

New York State Common Retirement Fund reduced its holdings in Penumbra, Inc. (NYSE:PEN) by 0.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 61,190 shares of the company’s stock after selling 409 shares during the quarter. New York State Common Retirement Fund owned approximately 0.16% of Penumbra worth $14,531,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of PEN. China Universal Asset Management Co. Ltd. bought a new stake in shares of Penumbra in the fourth quarter worth $573,000. State Street Corp grew its position in shares of Penumbra by 0.3% in the 3rd quarter. State Street Corp now owns 1,236,671 shares of the company’s stock valued at $240,298,000 after buying an additional 3,863 shares during the last quarter. Thrivent Financial for Lutherans increased its stake in shares of Penumbra by 3,832.3% in the third quarter. Thrivent Financial for Lutherans now owns 368,298 shares of the company’s stock valued at $71,564,000 after buying an additional 358,932 shares during the period. E. Ohman J or Asset Management AB raised its position in shares of Penumbra by 10.4% during the fourth quarter. E. Ohman J or Asset Management AB now owns 21,312 shares of the company’s stock worth $5,061,000 after acquiring an additional 2,000 shares during the last quarter. Finally, AlphaCentric Advisors LLC acquired a new position in shares of Penumbra in the third quarter worth approximately $777,000. Institutional investors own 88.88% of the company’s stock.

Insider Activity at Penumbra

In other news, CEO Adam Elsesser sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $242.96, for a total value of $3,644,400.00. Following the completion of the transaction, the chief executive officer now directly owns 837,582 shares of the company’s stock, valued at $203,498,922.72. This represents a 1.76 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Harpreet Grewal sold 167 shares of Penumbra stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $241.28, for a total value of $40,293.76. Following the sale, the director now owns 8,530 shares in the company, valued at $2,058,118.40. This trade represents a 1.92 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,219 shares of company stock valued at $4,426,439 over the last ninety days. Corporate insiders own 5.00% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. BTIG Research increased their target price on shares of Penumbra from $232.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Robert W. Baird increased their price objective on shares of Penumbra from $305.00 to $328.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 19th. JPMorgan Chase & Co. boosted their target price on shares of Penumbra from $230.00 to $285.00 and gave the company an “overweight” rating in a report on Wednesday, February 19th. UBS Group lifted their price objective on Penumbra from $305.00 to $320.00 and gave the stock a “buy” rating in a research report on Wednesday, February 19th. Finally, Citigroup upped their target price on Penumbra from $220.00 to $245.00 and gave the company a “neutral” rating in a research report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Penumbra presently has a consensus rating of “Moderate Buy” and an average target price of $292.64.

Penumbra Stock Down 3.5 %

PEN stock opened at $292.52 on Monday. The firm has a market capitalization of $11.27 billion, a PE ratio of 860.35, a P/E/G ratio of 2.83 and a beta of 0.53. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a twelve month low of $148.00 and a twelve month high of $310.00. The stock’s 50 day moving average is $259.09 and its 200-day moving average is $228.69.

Penumbra (NYSE:PEN) last issued its quarterly earnings data on Tuesday, February 18th. The company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.09. The business had revenue of $315.52 million for the quarter, compared to analysts’ expectations of $311.63 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. Sell-side analysts expect that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Penumbra Company Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.